Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

November 9, 2011

Primary Completion Date

November 28, 2018

Study Completion Date

November 28, 2018

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Imatinib mesylate

"* Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use"

Trial Locations (14)

13353

Charité University of Berlin - Clinic of Medicine - Hematology and Oncology, Berlin

16132

IRCCS A.O.U. San Martino, Genova

20052

Azienda Ospedaliera San Gerardo di Monza, Monza

20162

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC di Ematologia, Milan

Ospedale Niguarda Ca' Granda - U.O. Ematologia, Milan

27100

IRCCS Policlinico San Matteo Pavia - Istituto di Ematologia, Pavia

36100

Ospedale S. Bortolo (USSL 6), Vicenza

50134

Università di Firenze Azienda Ospedaliera - Universitaria Careggi, Florence

52621

Chaim Sheba Medical Center - Division of Hematology, BMT and CBB, Tel Litwinsky

89124

A.O. Bianchi-Melacrino-Morelli U.O. Ematologia, Reggio Calabria

95124

"Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele", Catania

H3T 1E2

McGill University - Jewish General Hospital Division of Hematology and Department of Oncology, Montreal

00142

Universita di Tor Vergata Ospedale S. Eugenio, Rome

Unknown

Hospital Universitario Miguel Servet - Hematologia, Zaragoza

All Listed Sponsors
lead

University of Milano Bicocca

OTHER

NCT01578213 - Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients | Biotech Hunter | Biotech Hunter